BIRMINGHAM, Ala. and TORONTO, April 19 Atherotech Inc. announced it will exhibit its VAP® Cholesterol Test in booth #1305 at Internal Medicine 2010, the annual scientific meeting of the American College of Physicians (ACP). The meeting takes place April 22-24, 2010, at the Metro Toronto Convention Centre in Toronto, Canada.
Advertisement
The VAP Test reports 22 separate components of cholesterol in a single test, including Lp(a), apoB, apoAI, and the apoB/apoAI ratio, at no additional cost, which saves health care dollars and maximizes risk identification. The VAP Test also identifies markers of metabolic syndrome, often associated with early diabetes.
Advertisement
"The VAP Cholesterol Test is gaining momentum as the preferred lipid test," said Atherotech Chief Medical Officer Michael E. Cobble, M.D. "Internal Medicine 2010 attendees will learn how we're complementing our VAP Test with the addition of cardiometabolic and genetic testing, giving physicians and cardiology practices a single source for multiple test panels."
Atherotech provides physicians with a single source for the VAP Cholesterol Test and more than a dozen cardiovascular and metabolic tests. Cardiometabolic testing available through Atherotech includes C-Reactive Protein (hsCRP), LpPLA2, ApoE genotype, NT-proBNP, Cystatin-C, T3 and T4 when TSH is abnormal, plus gamma-glutamyl transferase (GGT), a recognized cardiovascular risk biomarker.
Atherotech representatives will be available to discuss new research, the VAP Test and cardiometabolic test options throughout the conference. Blood draws will be provided to qualified attendees during regular exhibit hours. Unlike the standard lipid profile, the VAP Test directly measures LDL, therefore fasting is not required.
The VAP Test is available in Canada by direct order from Atherotech and in the U.S. by direct order and major reference laboratories. For more information call 877.901.8510 or visit www.atherotech.com.
About Atherotech Inc.
Atherotech is a CLIA-certified clinical reference laboratory and cardiodiagnostic company focusing on cardiometabolic tests, including the company's patented VAP Cholesterol Test, which reports the cholesterol content of all lipids, components and subclasses. The VAP Test is the first cholesterol profile to comply with updated National Cholesterol Education Program ATP III recommendations for direct LDL measurement, which is accurate with non-fasting samples. It is the only advanced lipid profile that routinely reports all three lipoprotein parameters considered necessary by the American Diabetes Association and American College of Cardiology expert consensus guidelines. The VAP Test is available through national and regional diagnostic laboratories and is reimbursed by many of the largest private insurers as well as Medicare. For more information, visit www.atherotech.com.
SOURCE Atherotech Inc.
